JP2020505025A - 免疫工学的な改変をした多能性細胞 - Google Patents

免疫工学的な改変をした多能性細胞 Download PDF

Info

Publication number
JP2020505025A
JP2020505025A JP2019538202A JP2019538202A JP2020505025A JP 2020505025 A JP2020505025 A JP 2020505025A JP 2019538202 A JP2019538202 A JP 2019538202A JP 2019538202 A JP2019538202 A JP 2019538202A JP 2020505025 A JP2020505025 A JP 2020505025A
Authority
JP
Japan
Prior art keywords
protein
cells
hla
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019538202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505025A5 (https=
Inventor
シュレプファー ソニヤ
シュレプファー ソニヤ
デュース トバイアス
デュース トバイアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Los Angeles UCLA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020505025A publication Critical patent/JP2020505025A/ja
Publication of JP2020505025A5 publication Critical patent/JP2020505025A5/ja
Priority to JP2022208126A priority Critical patent/JP2023052079A/ja
Priority to JP2025003516A priority patent/JP2025069169A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/005—Vectors comprising a special translation-regulating system cell cycle specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019538202A 2017-01-13 2018-01-14 免疫工学的な改変をした多能性細胞 Pending JP2020505025A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022208126A JP2023052079A (ja) 2017-01-13 2022-12-26 免疫工学的な改変をした多能性細胞
JP2025003516A JP2025069169A (ja) 2017-01-13 2025-01-09 免疫工学的な改変をした多能性細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445969P 2017-01-13 2017-01-13
US62/445,969 2017-01-13
PCT/US2018/013688 WO2018132783A1 (en) 2017-01-13 2018-01-14 Immunoengineered pluripotent cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022208126A Division JP2023052079A (ja) 2017-01-13 2022-12-26 免疫工学的な改変をした多能性細胞

Publications (2)

Publication Number Publication Date
JP2020505025A true JP2020505025A (ja) 2020-02-20
JP2020505025A5 JP2020505025A5 (https=) 2021-02-25

Family

ID=61148505

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019538202A Pending JP2020505025A (ja) 2017-01-13 2018-01-14 免疫工学的な改変をした多能性細胞
JP2022208126A Pending JP2023052079A (ja) 2017-01-13 2022-12-26 免疫工学的な改変をした多能性細胞
JP2025003516A Pending JP2025069169A (ja) 2017-01-13 2025-01-09 免疫工学的な改変をした多能性細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022208126A Pending JP2023052079A (ja) 2017-01-13 2022-12-26 免疫工学的な改変をした多能性細胞
JP2025003516A Pending JP2025069169A (ja) 2017-01-13 2025-01-09 免疫工学的な改変をした多能性細胞

Country Status (12)

Country Link
US (2) US20190376045A1 (https=)
EP (1) EP3568464A1 (https=)
JP (3) JP2020505025A (https=)
KR (2) KR20240095477A (https=)
CN (1) CN110177869A (https=)
AU (2) AU2018207649B2 (https=)
BR (1) BR112019014257A2 (https=)
CA (1) CA3049766A1 (https=)
EA (1) EA201991692A1 (https=)
IL (1) IL267616A (https=)
MX (1) MX2019008413A (https=)
WO (1) WO2018132783A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022191216A1 (https=) * 2021-03-09 2022-09-15
JP2023052079A (ja) * 2017-01-13 2023-04-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
JP2023521157A (ja) * 2020-04-06 2023-05-23 アールエックスセル インコーポレーテッド 低免疫原性の細胞ならびにそれらの産生のための方法および組成物
JP2023520997A (ja) * 2020-03-25 2023-05-23 サナ バイオテクノロジー，インコーポレイテッド 神経学的障害及び神経学的病態の処置のための低免疫原性神経細胞
JP2023545056A (ja) * 2020-10-09 2023-10-26 サナ バイオテクノロジー，インコーポレイテッド ＣＤ４７－ＳＩＲＰα封鎖剤を使用して安全殺傷機構を誘発する方法
JP2023552441A (ja) * 2020-12-07 2023-12-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＳＩＲＰ－αエンゲージャーによる自然免疫細胞のサイレンシング
JP2024514649A (ja) * 2021-04-16 2024-04-02 ビーム セラピューティクス インク． 肝細胞の遺伝子修飾

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
EA201891338A1 (ru) 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
CN110637083A (zh) * 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
CN120041380A (zh) 2017-06-12 2025-05-27 西奈卫生系统公司 无需全身性免疫遏制的同种异体移植物耐受
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US20210308183A1 (en) * 2018-07-17 2021-10-07 The Regents Of The University Of California Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
BR112021000637A2 (pt) * 2018-07-17 2021-04-13 The Regents Of The University Of California Célula cardíaca hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença cardíaca, método para produzir uma população de células cardíacas hipoimunes, célula endotelial hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença vascular, método para produzir uma população de células endoteliais hipoimunes, neurônio dopaminérgico hipoimune isolado, método para tratar um paciente que sofre de uma doença ou afecção neurodegenerativa, método para produzir uma população de neurônios dopaminérgicos hipoimunes, célula de ilhota pancreática hipoimune isolada, método para tratar um paciente que sofre de diabetes, método para produzir uma população de células de ilhota pancreática hipoimunes, célula de epitélio pigmentado da retina (rpe) hipoimune isolada, método para tratar um paciente que sofre de uma afecção ocular, e método para produzir uma população de células de epitélio pigmentado da retina (rpe) hipoimunes
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
CN113195724A (zh) * 2018-09-26 2021-07-30 新加坡国立大学 低免疫原性的工程化人类间充质基质细胞，制备方法和试剂盒
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111424016A (zh) * 2019-01-09 2020-07-17 复旦大学 降低细胞免疫原性的诱导型多能干细胞系及建立方法
KR20210128440A (ko) * 2019-02-15 2021-10-26 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 범용 공여자 줄기 세포 및 관련 방법
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020231882A2 (en) * 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
US12391923B2 (en) 2019-06-26 2025-08-19 The Regents Of The University Of California SIRPα-silenced natural killer (NK) cells
TW202115245A (zh) * 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
EP4022037A1 (en) 2019-07-10 2022-07-06 Helmuth Heinrich Kunz Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro
JP2022543112A (ja) * 2019-08-01 2022-10-07 サナ バイオテクノロジー，インコーポレイテッド Ｄｕｘ４発現細胞およびそれらの使用
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11104918B2 (en) * 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
CA3153700A1 (en) * 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
JP2022551975A (ja) * 2019-10-15 2022-12-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｆｃ封鎖を介する移植細胞保護
AU2021207810A1 (en) 2020-01-13 2022-08-04 Sana Biotechnology, Inc. Modification of blood type antigens
EP4585223A3 (en) 2020-01-15 2025-07-30 The Regents of the University of California Transplanted cell protection via inhibition of polymorphonuclear cells
CA3165076A1 (en) * 2020-01-17 2021-07-22 Ryan Clarke Safety switches for regulation of gene expression
EP4138893A4 (en) * 2020-04-21 2024-06-12 Intima Bioscience, Inc. CELLULAR VACCINE PLATFORM AND METHODS OF USE THEREOF
EP4149525A4 (en) * 2020-05-15 2024-08-28 Rxcell Inc. HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
CN112342196A (zh) * 2020-08-18 2021-02-09 未来智人再生医学研究院(广州)有限公司 一种免疫兼容可逆的通用型多能干细胞及其应用
EP4232468A4 (en) * 2020-10-20 2025-03-19 Replay Holdings, Inc. Methods and compositions for cellular therapy
CN114457021A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd47抗体的多能干细胞及其衍生物与应用
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN114107211B (zh) * 2020-12-04 2025-09-30 未来智人再生医学研究院(广州)有限公司 一种多能干细胞及其衍生物
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
KR20230146007A (ko) 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
CA3212370A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
EP4313087A4 (en) * 2021-03-30 2025-03-19 The Regents of the University of California PROTECTION OF TRANSPLANTED CELLS VIA MODIFIED FC RECEPTORS
EP4347810A4 (en) * 2021-05-24 2025-06-04 Sangamo Therapeutics, Inc. ZINC FINGER NUCLEASES TARGETING CIITA
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
WO2023008918A1 (ko) * 2021-07-28 2023-02-02 의료법인 성광의료재단 B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
TW202321435A (zh) 2021-08-11 2023-06-01 美商薩那生物科技公司 用於改變低免疫原性細胞中之基因表現之可誘導系統
KR20240073006A (ko) 2021-08-11 2024-05-24 사나 바이오테크놀로지, 인크. 동종이계 세포 요법을 위한 유전자 변형된 1차 세포
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
CN113801881B (zh) * 2021-08-27 2024-02-20 浙江大学 超级增强子基因序列在促进人b2m基因表达中的用途
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
KR20240142624A (ko) * 2022-01-10 2024-09-30 사나 바이오테크놀로지, 인크. 만능줄기세포에서 분화된 면역저하 베타세포 및 관련 용도 및 방법
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN114958768B (zh) * 2022-06-02 2023-03-24 健颐生物科技发展(山东)有限公司 Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
CN117343962A (zh) * 2022-06-29 2024-01-05 中国科学院上海营养与健康研究所 免疫兼容型人多能干细胞、其制备方法及应用
EP4547825A1 (en) 2022-07-01 2025-05-07 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
CN117384851B (zh) * 2022-07-11 2025-11-21 士泽生物医药（苏州）有限公司 一种表达faslg的通用型细胞及其制备方法
CN117431217A (zh) * 2022-07-12 2024-01-23 上海驯鹿生物技术有限公司 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity
GB202212144D0 (en) * 2022-08-19 2022-10-05 Resolution Therapeutics Ltd Cells for therapy
WO2024097315A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Cell therapy products and methods for producing same
WO2024107420A1 (en) * 2022-11-15 2024-05-23 The Board Of Trustees Of The Leland Stanford Junior University Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine
CN118147077B (zh) * 2022-12-07 2025-09-26 士泽生物医药（苏州）有限公司 一种表达gsn的通用型细胞及其制备方法
CN118207165B (zh) * 2022-12-07 2026-03-20 士泽生物医药（苏州）有限公司 一种表达stc1的通用型细胞及其制备方法
GB202218755D0 (en) * 2022-12-13 2023-01-25 Replay Holdings Llc Compositions and methods for non-immunogenicity
JP2026501446A (ja) * 2022-12-16 2026-01-15 ゼルスマート バイオ‐ファーマシューティカル （スズホウ） シーオー．， エルティーディー． ユニバーサル細胞及びその製造方法
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024169917A1 (zh) * 2023-02-16 2024-08-22 士泽生物医药（苏州）有限公司 通用型细胞及其制备方法
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
WO2025003393A1 (en) 2023-06-30 2025-01-02 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells
KR102740042B1 (ko) * 2023-07-12 2024-12-06 ㈜바이오솔빅스 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
AU2024328949A1 (en) 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
CN119351338B (zh) * 2023-09-15 2026-01-23 士泽生物医药（苏州）有限公司 一种表达cd300ld的低免疫原性细胞及其制备方法
WO2025096757A1 (en) 2023-11-01 2025-05-08 Sana Biotechnology, Inc. Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025230941A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Hypoimmunogenic cell mixtures and methods of use thereof
WO2025230947A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Engineered hepatocytes for secreting polypeptides
CN121006322A (zh) * 2024-05-22 2025-11-25 上海苹谱医疗科技有限公司 一种通用型工程化细胞及其制备方法与应用
WO2025259640A1 (en) * 2024-06-14 2025-12-18 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for bioengineering hypoimmunogenic organs, tissues and cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164740A1 (en) * 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
WO2016183041A2 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US20040053836A1 (en) * 2002-04-22 2004-03-18 Philipp Mayer-Kuckuk Method for modulating the production of a selected protein in vivo
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
DK2438160T3 (en) * 2009-06-05 2016-01-11 Cellular Dynamics Int Inc Reprogramming of T cells and hematopoietic cells
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US20150056225A1 (en) * 2012-04-17 2015-02-26 University Of Washington Through Its Center For Commercialization HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof
CA2940460A1 (en) * 2014-03-07 2015-09-11 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
KR20170137079A (ko) * 2015-03-11 2017-12-12 셀렉티스 그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
JP6928604B2 (ja) * 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CN110177869A (zh) * 2017-01-13 2019-08-27 加利福尼亚大学董事会 免疫改造的多能细胞
WO2020231882A2 (en) * 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164740A1 (en) * 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
WO2016183041A2 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023052079A (ja) * 2017-01-13 2023-04-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
JP2023520997A (ja) * 2020-03-25 2023-05-23 サナ バイオテクノロジー，インコーポレイテッド 神経学的障害及び神経学的病態の処置のための低免疫原性神経細胞
JP2023521157A (ja) * 2020-04-06 2023-05-23 アールエックスセル インコーポレーテッド 低免疫原性の細胞ならびにそれらの産生のための方法および組成物
JP2023545056A (ja) * 2020-10-09 2023-10-26 サナ バイオテクノロジー，インコーポレイテッド ＣＤ４７－ＳＩＲＰα封鎖剤を使用して安全殺傷機構を誘発する方法
JP2023552441A (ja) * 2020-12-07 2023-12-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＳＩＲＰ－αエンゲージャーによる自然免疫細胞のサイレンシング
JPWO2022191216A1 (https=) * 2021-03-09 2022-09-15
WO2022191216A1 (ja) * 2021-03-09 2022-09-15 国立研究開発法人理化学研究所 低免疫原性網膜色素上皮細胞の製造方法
JP2024514649A (ja) * 2021-04-16 2024-04-02 ビーム セラピューティクス インク． 肝細胞の遺伝子修飾

Also Published As

Publication number Publication date
CN110177869A (zh) 2019-08-27
AU2018207649A1 (en) 2019-07-11
JP2023052079A (ja) 2023-04-11
AU2024256086A1 (en) 2024-11-28
CA3049766A1 (en) 2018-07-19
KR20190103373A (ko) 2019-09-04
WO2018132783A1 (en) 2018-07-19
BR112019014257A2 (pt) 2020-04-28
MX2019008413A (es) 2019-09-13
AU2018207649B2 (en) 2024-08-01
US20230348862A1 (en) 2023-11-02
EP3568464A1 (en) 2019-11-20
KR20240095477A (ko) 2024-06-25
US20190376045A1 (en) 2019-12-12
EA201991692A1 (ru) 2019-12-30
NZ754898A (en) 2023-11-24
IL267616A (en) 2019-08-29
JP2025069169A (ja) 2025-04-30

Similar Documents

Publication Publication Date Title
US20230348862A1 (en) Immunoengineered pluripotent cells
AU2019305586B2 (en) Chimeric antigen receptor T cells derived from immunoengineered pluripotent stem cells
US12221622B2 (en) Modified pluripotent cells
JP6933898B2 (ja) 養子細胞治療製品を製造するための誘導多能性幹細胞の適用
US12492382B2 (en) Blood type O Rh—hypo-immunogenic cells
US20240091274A1 (en) TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION
CN116234906A (zh) 血型抗原的修饰
EP4585223A2 (en) Transplanted cell protection via inhibition of polymorphonuclear cells
EA053043B1 (ru) Модифицированные плюрипотентные клетки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220830